SLGL · Sol-Gel Technologies Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $19.39M | $11.54M | $1.55M | $3.88M | $31.27M | $8.77M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $22.80M | $17.80M | $23.54M | $12.68M | $20.38M | $27.91M |
| SG&A | $4.18M | $5.75M | $7.37M | $7.45M | $8.45M | $11.09M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $109.0K | $233.0K | $342.0K | $562.0K | $880.0K | $946.0K |
| Operating Income | ($7.54M) | ($12.01M) | ($29.30M) | ($16.24M) | $2.96M | ($30.23M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $0 | - |
| Net Income | ($6.13M) | ($10.58M) | ($27.24M) | ($14.92M) | $3.22M | ($29.29M) |
| EPS - Basic | ($2.19) | ($3.80) | ($10.10) | ($6.50) | ($13.00) | - |
| EPS - Diluted | ($2.19) | ($3.80) | ($10.10) | ($6.50) | ($13.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.03M | $19.49M | $7.51M | $12.45M | $20.09M | $7.12M |
| Accounts Receivable | $1.97M | $3.60M | $62.0K | $7.86M | $13.06M | $2.15M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $735.0K | $1.26M | $154.0K | $766.0K | $766.0K | $1.20M |
| Current Assets | $26.97M | $31.30M | $41.17M | $43.05M | $57.11M | $53.40M |
| Total Assets | $29.92M | $35.85M | $45.29M | $46.63M | $69.19M | $59.16M |
| Current Liabilities | $6.17M | $5.29M | $4.52M | $3.33M | $11.69M | $5.96M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.11M | $7.00M | $6.64M | $4.42M | $13.60M | $8.31M |
| Stockholders' Equity | $22.81M | $28.85M | $38.64M | $42.21M | $55.59M | $50.85M |
| Retained Earnings | ($237.01M) | ($230.88M) | ($220.30M) | ($193.06M) | ($178.14M) | ($181.36M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $322.0K | ($13.89M) | ($17.73M) | ($9.48M) | ($7.69M) | ($25.24M) |
| Investing Cash Flow | ($8.58M) | $26.69M | ($9.74M) | $1.70M | $19.87M | ($2.69M) |
| Financing Cash Flow | $6.0K | $0 | $21.81M | $15.0K | $837.0K | $26.46M |
| CapEx | $47.0K | $2.0K | $134.0K | $171.0K | $143.0K | $449.0K |
| Free Cash Flow | $275.0K | ($13.89M) | ($17.86M) | ($9.65M) | ($7.83M) | ($25.69M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -38.9% | -104.1% | -1885.8% | -418.3% | 9.5% | -344.7% |
| EBITDA margin | -38.3% | -102.1% | -1863.8% | -403.9% | 12.3% | -333.9% |
| Net margin | -31.6% | -91.7% | -1752.8% | -384.3% | 10.3% | -333.9% |
| Free cash flow margin | 1.4% | -120.4% | -1149.5% | -248.6% | -25.1% | -292.9% |
| FCF / Net income | -0.04 | 1.31 | 0.66 | 0.65 | -2.43 | 0.88 |
| R&D / Revenue | 117.6% | 154.3% | 1514.9% | 326.6% | 65.2% | 318.2% |
| SG&A / Revenue | 21.5% | 49.8% | 474.5% | 191.7% | 27.0% | 126.5% |
| Effective tax rate | - | - | - | - | 0.0% | - |
| Return on assets | -20.5% | -29.5% | -60.1% | -32.0% | 4.7% | -49.5% |
| Return on equity | -26.9% | -36.7% | -70.5% | -35.4% | 5.8% | -57.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.37 | 5.92 | 9.10 | 12.93 | 4.88 | 8.95 |
| Quick ratio | 4.37 | 5.92 | 9.10 | 12.93 | 4.88 | 8.95 |
| Cash ratio | 1.79 | 3.69 | 1.66 | 3.74 | 1.72 | 1.19 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.24 | 1.17 | 1.10 | 1.24 | 1.16 |
| Liabilities / Assets | 0.24 | 0.20 | 0.15 | 0.09 | 0.20 | 0.14 |
| Efficiency | ||||||
| Asset turnover | 0.65 | 0.32 | 0.03 | 0.08 | 0.45 | 0.15 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 37d | 114d | 15d | 739d | 152d | 90d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 5.1x | 9.0x | 7.7x | 25.0x | 30.0x | - |
| P / S | 6.1x | 22.5x | 192.6x | 271.6x | 53.4x | - |
| EV / EBITDA | - | - | - | - | 429.4x | - |
| Growth | ||||||
| Revenue growth (YoY) | 68.0% | 642.5% | -60.0% | -87.6% | 256.5% | -61.7% |
| Revenue CAGR (3y) | 70.9% | -28.3% | -43.8% | -44.7% | 523.5% | 269.4% |
| Revenue CAGR (5y) | 17.2% | -12.8% | 64.5% | 86.1% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 37.3% | 59.0% | -80.4% | - | - | -16.5% |
| Net income growth (YoY) | 42.1% | 61.2% | -82.5% | - | - | -19.0% |
| EPS growth (YoY) | 42.4% | 62.4% | -55.4% | 50.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 22.2% | -85.0% | -23.2% | 69.5% | -11.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -20.9% | -25.3% | -8.5% | -24.1% | 9.3% | -3.1% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-5.00
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sol-Gel Technologies Ltd. against the 5 most active filers in the same SIC group.